



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kocsis <i>et al.</i>	Confirmation No.: 5014
Application No.: 10/584,661	Art Unit: 1617
Filed: September 19, 2006	Examiner: Kim, Jennifer M.
For: Novel Pharmaceutical Compositions With Increased Activity	Atty. Docket: 0103-0004

Response to Restriction Requirement

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action, a Restriction Requirement, mailed on April 21, 2009, in connection with the above-identified application, the applicants provide the following response.

Restriction

In the Restriction Requirement, the Examiner restricted the claims into the following eight (8) groups of claims:

Group I: Claims 1-8 (in parts), 10-15 (in parts), 17 (in parts) and 18-23 (in parts), directed to a pharmaceutical composition which comprises a sodium channel blocker in combination with a selective serotonin uptake inhibitor and the use of the composition for the treatment of alcohol addiction.

Group II: Claims 1-8 (in parts), 10-15 (in parts), 17 (in parts) and 18-23 (in parts), directed to a pharmaceutical composition which comprises a sodium channel blocker in combination with a selective serotonin uptake inhibitor and the use of the composition for the treatment of incontinence of faeces and urine.

Group III: Claims 1-8 (in parts), 10-15 (in parts), 17 (in parts) and 18-23 (in parts), directed to a pharmaceutical composition which comprises a sodium channel